Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future
Abstract Amyloid β protein (Aβ) is the main component of neuritic plaques in Alzheimer’s disease (AD), and its accumulation has been considered as the molecular driver of Alzheimer’s pathogenesis and progression. Aβ has been the prime target for the development of AD therapy. However, the repeated f...
Main Authors: | Yun Zhang, Huaqiu Chen, Ran Li, Keenan Sterling, Weihong Song |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-06-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-023-01484-7 |
Similar Items
-
Mitochondrial β-amyloid in Alzheimer's disease.
by: Borger, E, et al.
Published: (2011) -
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
by: Chenghuan Song, et al.
Published: (2022-03-01) -
An “Amyloid‐β Cleaner” for the Treatment of Alzheimer's Disease by Normalizing Microglial Dysfunction
by: Ruiyuan Liu, et al.
Published: (2020-01-01) -
Biology of Aβ Amyloid in Alzheimer's Disease
by: Thomas Wisniewski, et al.
Published: (1997-01-01) -
β-Amyloid: The Key Peptide in the Pathogenesis of Alzheimer’s Disease
by: Xiaojuan eSun, et al.
Published: (2015-09-01)